To control the Jak-STAT pathway
activation, three main negative feedback mechanisms have been proposed.
The IFNAR-1 significance can be observed from a study where restored IFNAR-1 expression alone was able to restore defective JAK-STAT pathway
, STAT-1 and STAT-3 phosphorylation and anti-HCV response in IFN- resistant cell lines.
The binding of IL-31 to its receptors activates powerful signalling pathways (i.e., the activation of Janus kinase JAK1 and JAK2 and the start of JAK-STAT pathway
Another proinflammatory cytokine, IL-1[beta], is involved in the pathogenesis of the neuropathic pain component of RA regulated by the JAK-STAT pathway
Kobori, "Interferon-[gamma] biphasically regulates angiotensinogen expression via a JAK-STAT pathway
and suppressor of cytokine signaling 1 (SOCS1) in renal proximal tubular cells," The FASEB Journal, vol.
The results could mean "that inhibition of the JAK-STAT pathway
may be a new therapeutic target for AD," wrote the study's lead author, Robert Bissonnette, MD, president of Innovaderm Research in Montreal (Br J Dermatol.
It is well known that the Jak-STAT pathway
can regulate cell growth, apoptosis, immunity, and inflammatory responses and because of its significance in the immune response, the Jak-STAT pathway
is often exploited by pathogens .
When IL-12 is a ligand for the JAK-STAT pathway
in macrophages, a proinflammatory response of Th1 is produced, but when IL-10 is present, IL-12's proinflammatory effects are downregulated (Figure 1).
Activation of the JAK-STAT pathway
has also been demonstrated to confer cardioprotection in both in vitro and in vivo IR models and be involved in the early-phase and late-phase protection induced by IPC [21-23].
However, it is still not known whether DJC acts via the JAK-STAT pathway
. In this study, we hypothesized that DJC may improve renal function via a mechanism that involves JAK-STAT pathway
activation and antioxidant activity.
Progression of liver disease can be controlled by a number of cellular mediators among which JAK-STAT pathway
plays a significant role.
Several of these newly discovered mutations raise the possibility of targeting subpopulations of JMML cases with existing drugs: Janus kinase (JAK) inhibitors, currently used to treat certain other bone marrow and blood cancers such as polycythemia vera, might inhibit signaling through a hyperactive JAK-STAT pathway
identified in some patients, while other agents such as 5-azacytidine, most commonly used as a treatment for a blood disorder known as myelodysplastic syndrome, could be used to reduce excessive epigenetic DNA methylation seen in others.